(Bloomberg) -- The world’s biggest insulin maker is teaming up with a unit of IBM to crunch data on how people are managing their diabetes, the latest collaboration of its kind between pharmaceutical and technology companies.

Novo Nordisk A/S plans to gather information from patients using its treatments and devices to develop more advanced ways to keep the disease in check, the Danish company said in a statement Thursday. Novo’s partner Watson, International Business Machine Corp.’s cognitive computing platform, can process vast amounts of data to uncover user patterns and suggest possibilities for improved diabetes care.

Register or login for access to this item and much more

All Information Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access